This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Steinberg, G. K. Articles by Gross, T. Search for Related Content PubMed PubMed Citation Articles by Steinberg, G. K. Articles by Gross, T.

Stroke, Vol 19, 1112-1118, Copyright © 1988 by American Heart Association

ARTICLES

Dextromethorphan protects against cerebral injury following transient focal ischemia in rabbits

GK Steinberg, CP George, R DeLaPaz, DK Shibata and T Gross
Division of Neurosurgery, Stanford University Medical Center, California.

We investigated dextromethorphan, both a dextrorotatory opioid derivative and a clinically tested N-methyl-D-aspartate (NMDA) receptor antagonist, in a rabbit model of transient focal cerebral ischemia. Fourteen rabbits were randomly assigned to treatment with a 20 mg/kg i.v. loading dose followed by a 10 mg/kg/hr infusion of 0.4% dextromethorphan in normal saline or with an equivalent volume of normal saline alone. One hour after treatment, the rabbits underwent a 1-hour occlusion of the left internal carotid and anterior cerebral arteries followed by 4 hours of reperfusion. The seven dextromethorphan- treated rabbits showed a significant decrease in the area of neocortical severe ischemic neuronal damage (10.5%) compared with the seven normal saline-treated controls (49.6%, p less than 0.001). The dextromethorphan-treated rabbits also demonstrated significantly smaller areas of cortical edema (10.2%) on magnetic resonance imaging than the controls (38.6%, p less than 0.01). Analysis of somatosensory evoked potentials revealed recovery of the ipsilateral amplitude to contralateral values within 5 minutes of reperfusion in the dextromethorphan-treated rabbits but not in the controls (p less than 0.01). In our rabbit model of transient focal cerebral ischemia, dextromethorphan appears to protect the brain against ischemic neuronal damage and edema, as well as to promote neurophysiologic recovery. This clinically available drug should be further investigated as having potential therapeutic value in the treatment of stroke.

This article has been cited by other articles:

				G. Li, G. Cui, N.-S. Tzeng, S.-J. Wei, T. Wang, M. L. Block, and J.-S. Hong Femtomolar concentrations of dextromethorphan protect mesencephalic dopaminergic neurons from inflammatory damage FASEB J, April 1, 2005; 19(6): 489 - 496. [Abstract] [Full Text] [PDF]

				Y. Liu, L. Qin, G. Li, W. Zhang, L. An, B. Liu, and J.-S. Hong Dextromethorphan Protects Dopaminergic Neurons against Inflammation-Mediated Degeneration through Inhibition of Microglial Activation J. Pharmacol. Exp. Ther., April 1, 2003; 305(1): 212 - 218. [Abstract] [Full Text]

				A. P. Raval, K. R. Dave, D. Mochly-Rosen, T. J. Sick, and M. A. Perez-Pinzon epsilon PKC Is Required for the Induction of Tolerance by Ischemic and NMDA-Mediated Preconditioning in the Organotypic Hippocampal Slice J. Neurosci., January 15, 2003; 23(2): 384 - 391. [Abstract] [Full Text] [PDF]

				M. D. Ginsberg REVIEW {blacksquare} : Neuroprotection in Brain Ischemia: An Update (Part I Neuroscientist, March 1, 1995; 1(2): 95 - 103. [Abstract] [PDF]